STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy

Biomaterials

Volumn 163, Issue , 2018, Pages 67-75

  Leach, David G ^a   Dharmaraj, Neeraja ^b   Piotrowski, Stacey L ^b   Lopez Silva, Tania L ^a   Lei, Yu L ^c   Sikora, Andrew G ^d   Young, Simon ^b   Hartgerink, Jeffrey D ^a  

^a Rice University   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Extended drug release; Immunotherapy; Intratumoral injection; Peptide hydrogel; STINGel

Indexed keywords

COLLAGEN; DISEASES; HYDROGELS; PEPTIDES; TARGETED DRUG DELIVERY;

EXTENDED DRUG RELEASE; IMMUNOTHERAPY; INTRATUMORAL INJECTION; PEPTIDE HYDROGELS; STINGEL;

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; COLLAGEN; CYCLIC DINUCLEOTIDE; DINUCLEOTIDE; DRUG CARRIER; NANOMATERIAL; PEPTIDE; UNCLASSIFIED DRUG; CYCLIC NUCLEOTIDE; NANOFIBER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HISTOLOGY; HYDROGEL; IN VIVO STUDY; MALE; MOUSE; MOUTH CANCER; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DIMERIZATION; DRUG RELEASE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INTRALESIONAL DRUG ADMINISTRATION; NEOPLASM; PARTICLE SIZE; PROCEDURES; STATIC ELECTRICITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COLLAGEN; DELAYED-ACTION PREPARATIONS; DIMERIZATION; DRUG CARRIERS; DRUG LIBERATION; FEMALE; HUMANS; HYDROGELS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; MICE, INBRED C57BL; NANOFIBERS; NEOPLASMS; NUCLEOTIDES, CYCLIC; PARTICLE SIZE; PEPTIDES; STATIC ELECTRICITY;

EID: 85042126055     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2018.01.035     Document Type: Article

References (45)

1. Langer, R., New methods of drug delivery. Science 249:4976 (1990), 1527–1533.
2. Koshy, S.T., Ferrante, T.C., Lewin, S.A., Mooney, D.J., Injectable, porous, and cell-responsive gelatin cryogels. Biomaterials 35:8 (2014), 2477–2487.
3. Bae, K.H., Wang, L.S., Kurisawa, M., Injectable biodegradable hydrogels: progress and challenges. J. Mater. Chem. B 1:40 (2013), 5371–5388.
4. Langer, R., Vacanti, J.P., Tissue engineering. Science 260:5110 (1993), 920–926.
5. Silva, E.A., Mooney, D.J., Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 31:6 (2010), 1235–1241.
6. Shea, L.D., Smiley, E., Bonadio, J., Mooney, D.J., DNA delivery from polymer matrices for tissue engineering. Nat. Biotechnol. 17:6 (1999), 551–554.
7. Ali, O.A., Huebsch, N., Cao, L., Dranoff, G., Mooney, D.J., Infection-mimicking materials to program dendritic cells in situ. Nat. Mater. 8:2 (2009), 151–158.
8. Modena, A., Ciccarese, C., Iacovelli, R., Brunelli, M., Montironi, R., Fiorentino, M., Tortora, G., Massari, F., Immune checkpoint inhibitors and prostate cancer: a new Frontier?. Oncol Rev., 10(1), 2016, 293.
9. Margolin, K., The promise of molecularly targeted and immunotherapy for advanced melanoma. Curr. Treat. Options Oncol., 17(9), 2016, 48.
10. Economopoulou, P., Kotsantis, I., Psyrri, A., Checkpoint inhibitors in head and neck cancer: rationale, clinical activity, and potential biomarkers. Curr. Treat. Options Oncol., 17(8), 2016, 40.
11. Atkins, M.B., Larkin, J., Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. JNCI (J. Natl. Cancer Inst.), 108(6), 2016 djv414.
12. Hodi, F., Kluger, K.M., Sznol, M., et al. Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial: abstract CT001. 107th Annual Meeting of the American Association for Cancer Research AACR: New Orleans, LA, 2016.
13. Errico, A., Melanoma: CheckMate 067–frontline nivolumab improves PFS alone or in combination with ipilimumab. Nat. Rev. Clin. Oncol., 12, 2015, 435.
14. Hauschild, A., Garbe, C., Combined immunotherapy–a new standard in metastatic melanoma?. Nat. Rev. Clin. Oncol., 12, 2015.
15. Méry, B., Rancoule, C., Guy, J.-B., Espenel, S., Wozny, A.-S., Battiston-Montagne, P., Ardail, D., Beuve, M., Alphonse, G., Rodriguez-Lafrasse, C., Magné N., Preclinical models in HNSCC: a comprehensive review. Oral Oncol. 65 (2017), 51–56.
16. SEER Surveillance Epidemiology and End Results Fast Facts [Internet]. http://seer.cancer.gov/faststats/selections.php?#Output (Accessed June 06 2017).
17. SEER Cancer of the Oral Cavity and Pharynx - SEER Fast Fact Sheets. http://seer.cancer.gov/statfacts/html/oralcav.html (Accessed June 06 2017).
18. Stransky, N., Egloff, A.M., Tward, A.D., Kostic, A.D., Cibulskis, K., Sivachenko, A., Kryukov, G.V., Lawrence, M., Sougnez, C., McKenna, A., Shefler, E., Ramos, A.H., Stojanov, P., Carter, S.L., Voet, D., Cortés, M.L., Auclair, D., Berger, M.F., Saksena, G., Guiducci, C., Onofrio, R., Parkin, M., Romkes, M., Weissfeld, J.L., Seethala, R.R., Wang, L., Rangel-Escareño, C., Fernandez-Lopez, J.C., Hidalgo-Miranda, A., Melendez-Zajgla, J., Winckler, W., Ardlie, K., Gabriel, S.B., Meyerson, M., Lander, E.S., Getz, G., Golub, T.R., Garraway, L.A., Grandis, J.R., The mutational landscape of head and neck squamous cell carcinoma. Science (New York, N.Y.) 333:6046 (2011), 1157–1160.
19. Gooi, Z., Chan, J.Y.K., Fakhry, C., The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. Laryngoscope 126:4 (2016), 894–900.
20. Maxwell, J.H., Grandis, J.R., Ferris, R.L., HPV-associated head and neck cancer: unique features of epidemiology and clinical management. Annu. Rev. Med. 67 (2016), 91–101.
21. Seiwert, T.Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J.P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., Cheng, J.D., Chow, L.Q., Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17:7 (2016), 956–965.
22. Corrales, L., Glickman, Laura H., McWhirter, Sarah M., Kanne, David B., Sivick, Kelsey E., Katibah, George E., Woo, S.-R., Lemmens, E., Banda, T., Leong, Justin J., Metchette, K., Dubensky, Thomas W. Jr., Gajewski, Thomas F., Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11:7 (2015), 1018–1030.
23. Barber, G.N., STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15:12 (2015), 760–770.
24. Gadkaree, S.K., Fu, J., Sen, R., Korrer, M.J., Allen, C., Kim, Y.J., Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model. Head Neck J. Sci. Spec., 16(Suppl 1), 2017 3-n/a.
25. Burdette, D.L., Monroe, K.M., Sotelo-Troha, K., Iwig, J.S., Eckert, B., Hyodo, M., Hayakawa, Y., Vance, R.E., STING is a direct innate immune sensor of cyclic di-GMP. Nature 478:7370 (2011), 515–518.
26. Cerboni, S., Jeremiah, N., Gentili, M., Gehrmann, U., Conrad, C., Stolzenberg, M.-C., Picard, C., Neven, B., Fischer, A., Amigorena, S., Rieux-Laucat, F., Manel, N., Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. J. Exp. Med., 214(6), 2017, 1769.
27. AduroBiotech, NCT02675439: Study of the Safety and Efficacy of MIW815 (ADU-S100) in Patients with Advanced/Metastatic Solid Tumors or Lymphomas, February 5, 2016 ed., 2017, National Institute of Health, ClinicalTrails.gov.
28. Moore, E., Clavijo, P.E., Davis, R., Cash, H., Van Waes, C., Kim, Y., Allen, C., Established T cell–inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade. Cancer Immunol. Res., 4(12), 2016, 1061.
29. Moore, A.N., Hartgerink, J.D., Self-assembling multidomain peptide nanofibers for delivery of bioactive molecules and tissue regeneration. Accounts Chem. Res. 50:4 (2017), 714–722.
30. Aulisa, L., Dong, H., Hartgerink, J.D., Self-assembly of multidomain peptides: sequence variation allows control over cross-linking and viscoelasticity. Biomacromolecules 10:9 (2009), 2694–2698.
31. Kumar, V.A., Shi, S., Wang, B.K., Li, I.-C., Jalan, A.A., Sarkar, B., Wickremasinghe, N.C., Hartgerink, J.D., Drug-triggered and cross-linked self-assembling nanofibrous hydrogels. J. Am. Chem. Soc. 137:14 (2015), 4823–4830.
32. Li, I.C., Moore, A.N., Hartgerink, J.D., “Missing tooth” multidomain peptide nanofibers for delivery of small molecule drugs. Biomacromolecules 17:6 (2016), 2087–2095.
33. Dong, H., Paramonov, S.E., Aulisa, L., Bakota, E.L., Hartgerink, J.D., Self-assembly of multidomain Peptides: balancing molecular frustration controls conformation and nanostructure. J. Am. Chem. Soc. 129:41 (2007), 12468–12472.
34. Young, S.W., Dharmaraj, N., Piotrowski, S., Koshy, S.T., Li, W.A., Mooney, D.J., Sikora, A.G., Overcoming resistance to checkpoint inhibitors through a rationally-designed combinatorial immunotherapy approach. J. Oral Maxillofac. Surg. 75:10 (2017), e331–e332.
35. Young, S., Dharmaraj, N., Piotrowski, S., Koshy, S.T., Li, W.A., Mooney, D.J., Sikora, A.G., Overcoming resistance to checkpoint inhibitors through a rationally-designed combinatorial immunotherapy approach. J. Dent. Res., 96(A), 2017.
36. Judd, N.P., Winkler, A.E., Murillo-Sauca, O., Brotman, J.J., Law, J.H., Lewis, J.S., Dunn, G.P., Bui, J.D., Sunwoo, J.B., Uppaluri, R., ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Canc. Res. 72:1 (2012), 365–374.
37. Kumar, V.A., Liu, Q., Wickremasinghe, N.C., Shi, S., Cornwright, T.T., Deng, Y., Azares, A., Moore, A.N., Acevedo-Jake, A.M., Agudo, N.R., Pan, S., Woodside, D.G., Vanderslice, P., Willerson, J.T., Dixon, R.A., Hartgerink, J.D., Treatment of hind limb ischemia using angiogenic peptide nanofibers. Biomaterials 98 (2016), 113–119.
38. Kumar, V.A., Taylor, N.L., Shi, S., Wang, B.K., Jalan, A.A., Kang, M.K., Wickremasinghe, N.C., Hartgerink, J.D., Highly angiogenic peptide nanofibers. ACS Nano 9:1 (2015), 860–868.
39. Tamura, T., Yanai, H., Savitsky, D., Taniguchi, T., The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26:1 (2008), 535–584.
40. Lei, Y., Moore, C.B., Liesman, R.M., O'Connor, B.P., Bergstralh, D.T., Chen, Z.J., Pickles, R.J., Ting, J.P.Y., MAVS-mediated apoptosis and its inhibition by viral proteins. PLoS One, 4(5), 2009, e5466.
41. Klune, J.R., Dhupar, R., Cardinal, J., Billiar, T.R., Tsung, A., HMGB1: endogenous danger signaling. Mol. Med. 14:7–8 (2008), 476–484.
42. Bianchi, M.E., DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81:1 (2007), 1–5.
43. Burdette, D.L., Vance, R.E., STING and the innate immune response to nucleic acids in the cytosol. Nat. Immunol. 14:1 (2013), 19–26.
44. Yildiz, S., Alpdundar, E., Gungor, B., Kahraman, T., Bayyurt, B., Gursel, I., Gursel, M., Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cell-penetrating peptide or combined with CpG. Eur. J. Immunol. 45:4 (2015), 1170–1179.
45. McWhirter, S.M., Barbalat, R., Monroe, K.M., Fontana, M.F., Hyodo, M., Joncker, N.T., Ishii, K.J., Akira, S., Colonna, M., Chen, Z.J., Fitzgerald, K.A., Hayakawa, Y., Vance, R.E., A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J. Exp. Med. 206:9 (2009), 1899–1911.